Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto- head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Gastroenterology Council for Gut and Liver 2021-03-01
سلاسل:	Gut and Liver
الموضوعات:	comparative study infliximab adalimumab tumor necrosis factor-alpha colitis ulcerative
الوصول للمادة أونلاين:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl19433
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!